All In MedTech

FDA Clearance Tracker · P940015-S011

SYNVISC HYLAN G-F 20

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 9, 2008 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P940015-S011
Device name
SYNVISC HYLAN G-F 20
Applicant location
Cambridge, MA
Received
Feb 20, 2007
Decided
Jun 9, 2008
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P940015

Device type

Device class
Class III

Every decision under product code MOZ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE REPLACEMENT OF THE DILUTION STATEMENT FROM THE ?PRECAUTION? SECTION AND IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NONPHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS, E.G., ACETAMINOPHEN.

Source documents

Other decisions for Sanofi Genzyme Corp.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.